Original Research

A Phase II single-arm trial of palonosetron for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in malignant glioma patients receiving multidose irinotecan in combination with bevacizumab

Affronti ML, Woodring S, Peters KB, Herndon II JE, McSherry F, Healy PN, Desjardins A, Vredenburgh JJ, Friedman HS

Therapeutics and Clinical Risk Management 2017, 13:33-40

Published Date: 23 December 2016